Medifoxamine

An atypical antidepressant

Medifoxamine
[[File: Chemical structure of Medifoxamine |frameless|220px|alt=|]]
INN
Drug class
Routes of administration	Oral
Pregnancy category
Bioavailability
Metabolism	Hepatic
Elimination half-life
Excretion	Renal
Legal status	Rx-only
CAS Number	3239-44-9
PubChem	4053
DrugBank	DB08998
ChemSpider	3913
KEGG	D07355

Medifoxamine is an atypical antidepressant that was developed in the 1970s and used primarily in France and other European countries. It is known for its unique pharmacological profile, which distinguishes it from other antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs).

Pharmacology

Medifoxamine acts as a serotonin and dopamine reuptake inhibitor, which contributes to its antidepressant effects. Unlike many other antidepressants, it does not significantly affect the reuptake of norepinephrine. This selective action is thought to reduce the incidence of certain side effects commonly associated with other antidepressant classes.

Additionally, medifoxamine has been shown to possess anxiolytic properties, making it potentially useful in the treatment of anxiety disorders. Its mechanism of action also includes modulation of GABAergic activity, which may contribute to its calming effects.

Clinical Use

Medifoxamine was primarily prescribed for the treatment of major depressive disorder and anxiety disorders. It was favored for its relatively mild side effect profile compared to other antidepressants available at the time. Patients reported fewer issues with sedation, weight gain, and sexual dysfunction, which are common side effects of many antidepressants.

Side Effects

While medifoxamine is generally well-tolerated, some patients may experience side effects such as nausea, dizziness, and headache. Rarely, it may cause allergic reactions or hepatic issues, necessitating regular monitoring of liver function during treatment.

Discontinuation

Medifoxamine was eventually withdrawn from the market due to concerns over hepatotoxicity, which is the potential for causing liver damage. Despite its efficacy and favorable side effect profile, the risk of liver damage led to its discontinuation in the late 1990s.

Related pages

• Antidepressant
• Serotonin
• Dopamine
• Anxiety disorder
• Hepatotoxicity